Skip to Content

New Drug Approvals Archive - February 2007

See also: New Indications and Dosage Forms for February 2007

February 2007

Amrix (cyclobenzaprine) Extended-Release Capsules

Date of Approval: February 1, 2007
Company: ECR Pharmaceuticals
Treatment for: Muscle Spasm

Amrix is an extended-release formulation of the skeletal muscle relaxant cyclobenzaprine, indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.

Alli (orlistat) 60 mg Capsules

Date of Approval: February 7, 2007
Company: GlaxoSmithKline Consumer Healthcare
Treatment for: Weight Loss

Alli is an over-the-counter weight-loss product containing orlistat, the same ingredient in prescription strength Xenical. Alli is indicated for weight loss in overweight adults 18 years and older when used along with a reduced-calorie, low-fat diet.

Vyvanse (lisdexamfetamine dimesylate) Capsules

Date of Approval: February 23, 2007
Company: Shire plc
Treatment for: Attention Deficit Disorder

Vyvanse (lisdexamfetamine dimesylate) is an amphetamine derivative prodrug administered once-daily for the treatment of attention deficit hyperactivity disorder (ADHD) and binge-eating disorder.

New Drug Approvals Archive

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.